GTBP
GT Biopharma, Inc.
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Company with tickers: GTBP
CIK
109657
CUSIP
36254L308
Shares Outstanding
36,062,904
Website
https://www.gtbiopharma.com/
13F Activity (30d)
3 filings
2 filers
Registered funds — mutual funds, ETFs and closed-end funds — whose latest Form N-PORT portfolio report holds this stock, matched by the stock's CUSIP. Each row is one fund position with its size, value and weight in that fund.
Funds holding GTBP
5 fund positions| Fund | Ticker | Balance | Value | % of Fund | Side | Reported | Open |
|---|---|---|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND | — | 451,875 | $184,410 | 0.00% | Long | 2026-03-31 | |
| Fidelity Extended Market Index Fund | — | 21,852 | $10,445 | 0.00% | Long | 2026-02-28 | |
| Fidelity Series Total Market Index Fund | — | 3,559 | $1,701 | 0.00% | Long | 2026-02-28 | |
| Fidelity Total Market Index Fund | — | 2,196 | $1,050 | 0.00% | Long | 2026-02-28 | |
| Guggenheim Active Allocation Fund | GUG | 3 | $1 | 0.00% | Long | 2026-02-27 |
Showing 1–5 of 5 positions